Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Cyclophosphamide/glucocorticoids/rituximab

Herpes zoster infection and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chang H-H, et al. Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report. Oxford Medical Case Reports 2022 : 417-419, No. 12, Dec 2022. Available from: URL: http://doi.org/10.1093/omcr/omac134 Chang H-H, et al. Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report. Oxford Medical Case Reports 2022 : 417-419, No. 12, Dec 2022. Available from: URL: http://​doi.​org/​10.​1093/​omcr/​omac134
Metadaten
Titel
Cyclophosphamide/glucocorticoids/rituximab
Herpes zoster infection and lack of efficacy: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41820-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Bupivacaine